Literature DB >> 17723089

Clindamycin-induced Sweet's syndrome.

Brychan M Clark1, Diane C Homeyer, Kristen R Glass, Laurie C D'Avignon.   

Abstract

Drug-induced acute febrile neutrophilic dermatosis, or Sweet's syndrome, is rare and, to our knowledge, has not previously been associated with clindamycin therapy. We describe a 47-year-old woman with type 2 diabetes mellitus and end-stage renal disease requiring hemodialysis who developed Sweet's syndrome after receiving oral and intravenous clindamycin for a tooth infection. After the clindamycin was discontinued, the patient's clinical symptoms resolved over several days. Use of the Naranjo adverse drug reaction probability scale indicated a probable relationship between the patient's development of Sweet's syndrome and clindamycin therapy. Clinicians should be aware that Sweet's syndrome can occur with clindamycin treatment. Early recognition of this condition in conjunction with cessation of drug exposure, with or without antiinflammatory therapy, can produce complete recovery.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17723089     DOI: 10.1592/phco.27.9.1343

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  4 in total

1.  Antibiotic prescribing practices by dentists: a review.

Authors:  Najla Saeed Dar-Odeh; Osama Abdalla Abu-Hammad; Mahmoud Khaled Al-Omiri; Ameen Sameh Khraisat; Asem Ata Shehabi
Journal:  Ther Clin Risk Manag       Date:  2010-07-21       Impact factor: 2.423

2.  Sweet's syndrome associated with cellulitis - a challenging diagnosis.

Authors:  Cristina Resende; Rui Santos; Teresa Pereira; Celeste Brito
Journal:  An Bras Dermatol       Date:  2016 Jan-Feb       Impact factor: 1.896

Review 3.  Insights Into the Pathogenesis of Sweet's Syndrome.

Authors:  Michael S Heath; Alex G Ortega-Loayza
Journal:  Front Immunol       Date:  2019-03-12       Impact factor: 7.561

Review 4.  Immediate and Delayed Hypersensitivity Reactions to Antibiotics: Aminoglycosides, Clindamycin, Linezolid, and Metronidazole.

Authors:  Michelle Dilley; Bob Geng
Journal:  Clin Rev Allergy Immunol       Date:  2021-12-15       Impact factor: 10.817

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.